Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

STATUS

Recruiting
End date

Jul 12, 2025
participants needed

372
sponsor

Sanofi

Send

Updated on 19 February 2024

See if I qualify

cancer

estrogen

breast cancer

metastasis

hormone therapy

tamoxifen

adenocarcinoma

targeted therapy

endocrine therapy

estrogen receptor

adenocarcinoma of the breast

letrozole

advanced breast cancer

fulvestrant

stage iv breast cancer

anastrozole

exemestane

locally advanced breast cancer

immunological adjuvant

estrogen receptor-positive breast cancer

adjuvant

HER2

ESR1

oestrogen receptor positive breast cancer

er-positive breast cancer

estrogen receptor positive breast cancer

cancer metastatic

Summary

Primary Objective:

To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer.

Secondary Objectives:

To compare the overall survival in the 2 treatment arms
To assess the objective response rate in the 2 treatment arms.
To evaluate the disease control rate in the 2 treatment arms.
To evaluate the clinical benefit rate in the 2 treatment arms.
To evaluate the duration of response in the 2 treatment arms.
To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in the 2 treatment arms.
To evaluate the pharmacokinetics of SAR439859 as single agent.
To evaluate health related quality of life in the 2 treatment arms.
To compare the overall safety profile in the 2 treatment arms.

Description

The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days of study treatment), and an end of treatment (EOT) visit at least 30 days (or until the participant receive another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, death or upon participant's request.

An extension of recruitment for Chinese participants is planned in this study: After completion of randomization in the global part of the study, randomization will continue in China until approximately 90 Chinese participants are randomized.

Details

Condition	Breast Cancer Metastatic
Age	18years - 100years
Treatment	Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen, SAR439859
Clinical Study Identifier	NCT04059484
Sponsor	Sanofi
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	years or older
	Histological or cytological diagnosis of adenocarcinoma of the breast
	Locally advanced not amenable to radiation therapy or surgery in a curative intent, and/or metastatic disease
	ER positive status
	HER2 negative status
	Participants must have received no more than 1 prior chemotherapeutic or 1 targeted therapy regimen for advanced/metastatic disease
	In the main study, a prior treatment with a CDK 4/6 inhibitor is mandatory if this treatment is approved and can be reimbursed for this participant. The percentage of participants without previous CDK 4/6 inhibitor will be capped to 20%. In the Chinese extension cohort, previous treatment with a CDK 4/6 inhibitor will not be mandatory, and there will be no limitation to the number of participants nave to CDK4/6 inhibitor
	Participants must present a secondary endocrine resistance to endocrine therapy defined as: progression while on endocrine therapy after at least 6 months of treatment for advanced breast cancer, or relapse while on adjuvant endocrine therapy but after the first 2 years, or with a relapse within 12 months after completing adjuvant endocrine therapy
	Male or Female
Exclusion Criteria
	Eastern Cooperative Oncology Group performance status 2
	Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of SAR439859. Participants unable to swallow normally and to take capsules
	Participant with any other cancer. Adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant has been disease free for >3 years are allowed
	Severe uncontrolled systemic disease at screening
	Participants with known brain metastases that are untreated, symptomatic or require therapy to control symptoms
	Prior treatment with mammalian target of rapamycin inhibitors or any other selective estrogen receptor degrader (SERD) compound, except fulvestrant if stopped for at least3 months before randomization
	Treatment with drugs that have the potential to inhibit UGT less than 2 weeks before randomization
	Treatment with strong or moderate CYP3A/CYP2C8 inducers within 2 weeks before randomization
	Ongoing treatment with drugs that are substrate of P-glycoprotein (P gp) (dabigatran, digoxin, fexofenadine)
	Treatment with anticancer agents (including investigational drugs) less than 3 weeks before randomization
	Inadequate hematological, coagulation, renal and liver functions
	The above information is not intended to contain all considerations relevant
	to a patient's potential participation in a clinical trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

adenocarcinoma of the breast

letrozole

advanced breast cancer

fulvestrant

stage iv breast cancer

anastrozole

exemestane

locally advanced breast cancer

immunological adjuvant

estrogen receptor-positive breast cancer

adjuvant

HER2

ESR1

oestrogen receptor positive breast cancer

er-positive breast cancer

estrogen receptor positive breast cancer

cancer metastatic

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)